^
3d
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
P1/2, N=23, Active, not recruiting, Joshua Brody | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2026
Enrollment closed • Trial completion date
|
Keytruda (pembrolizumab) • Imbruvica (ibrutinib)
3d
MyD88 protein destabilization mitigates NF-κB-dependent protection against macrophage apoptosis. (PubMed, Cell Commun Signal)
However, compared to MyD88wt counterparts, MyD88D162E BMDMs had increased oxidative stress and dysfunctional mitochondria, along with reduced prosurvival Bcl-xL and BTK expression, rendering cells more prone to apoptosis, exacerbated by ibrutinib treatment...These findings underscore the importance of MyD88wt signaling for NF-κB activation, protecting against macrophage premature apoptosis at resting state. Targeting MyD88 quantity rather than just its signaling could be a promising strategy for MyD88-driven lymphoma treatment.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BTK (Bruton Tyrosine Kinase) • BCL2L1 (BCL2-like 1)
|
MYD88 wild-type
|
Imbruvica (ibrutinib)
5d
Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin. (PubMed, Cancer Innov)
The study concludes that metformin effectively mitigates ibrutinib-induced cardiotoxicity, including ventricular arrhythmia and cardiac dysfunction, by enhancing AMPK and PI3K-AKT pathway activity. These findings suggest that metformin holds potential as a therapeutic strategy to protect against the adverse cardiac effects associated with ibrutinib treatment, offering a promising approach for improving the cardiovascular safety of patients undergoing therapy for B cell cancers.
Journal
|
BTK (Bruton Tyrosine Kinase)
|
Imbruvica (ibrutinib) • metformin
6d
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors. (PubMed, JCI Insight)
BACKGROUNDInhibition of Bruton's tyrosine kinase with ibrutinib blocks the function of myeloid-derived suppressor cells (MDSC). The addition of nivolumab significantly increased circulating NK and CD8+ T cells and increased CD8+ T cell proliferation. Exploratory analyses suggest that MDSC and T cell gene expression and TCR repertoire diversity were differentially affected by BTK inhibition according to patient response.CONCLUSIONIbrutinib and nivolumab were well tolerated and affected MDSC and T cell function in patients with solid metastatic tumors.TRIAL REGISTRATIONClinicalTrials.gov NCT03525925.FUNDINGNIH; National Cancer Institute Cancer; National Center for Advancing Translational Sciences; Pelotonia.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3)
|
Opdivo (nivolumab) • Imbruvica (ibrutinib)
7d
The design, synthesis, and biological evaluation of 5,6,7,8-tetrahydropteridines as anti-inflammatory compounds. (PubMed, Org Biomol Chem)
Research has shown that Bruton's tyrosine kinase (BTK) is a critical regulator of the NLRP3 inflammasome and that the pharmacological inhibition of BTK using the FDA-approved inhibitor ibrutinib diminishes NLRP3-dependent inflammatory response...In our drug discovery efforts, we identified 5,6,7,8-tetrahydropteridines as underutilized scaffolds in medicinal chemistry. We report the synthesis of 5,6,7,8-tetrahydropteridines with potential as anti-inflammatory compounds.
Journal
|
BTK (Bruton Tyrosine Kinase) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
Imbruvica (ibrutinib)
8d
SA-002804: A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome; (clinicaltrials.gov)
P2, N=15, Active, not recruiting, Bnai Zion Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Dec 2024
Enrollment closed • Trial primary completion date
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
16d
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO) (ASH 2024)
The combination of the Bruton tyrosine kinase inhibitor (BTKi) ibrutinib, the BCL-2 inhibitor venetoclax (V), and the anti-CD20 monoclonal antibody (mAb) obinutuzumab (O) has demonstrated safety and efficacy in R/R and TN MCL (Le Gouill, Blood 2021). AVO is safe and active in pts with R/R and TP53-aberrant/transplant ineligible TN MCL. Preliminary efficacy and feasibility of an MRD-guided treatment approach is encouraging in this high-risk TN cohort B. Our data supports further investigation of a targeted triplet approach, and the phase II TN transplant eligible and TP53 wild type cohort is enrolling based on demonstrated safety and efficacy in cohort B. Updated results will be presented at the meeting.
Clinical • P1/2 data • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type • TP53 expression
|
clonoSEQ
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
16d
Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma (ASH 2024)
Introduction – We previously reported the efficacy and safety results of a combination of ibrutinib with rituximab in patients (pts) with mantle cell lymphoma (MCL) ≥ 65 years. Conclusions – Chemotherapy-free frontline therapy with AR is highly effective, safe, induces deep MRD negative responses and alters immune landscape in older pts with MCL. Randomized studies are needed to confirm whether this regimen can be the new first line standard treatment for older MCL patients.
Clinical
|
TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • SOX11 (SRY-Box Transcription Factor 11) • TBL1XR1 (TBL1X Receptor 1)
|
TP53 mutation
|
clonoSEQ
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • Calquence (acalabrutinib)
16d
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400) (ASH 2024)
Zanubrutinib is a second-generation BTKi with superior PFS and safety compared with ibrutinib (Brown NEJM 2023). Five-year follow up of the BOVen regimen demonstrates frequent uMRD4 in PB (96%) and BM (92%), and uMRD4 was durable with a median MRD4-free survival of 34 mo. Retreatment with zanubrutinib-venetoclax was also well-tolerated and effective. A phase 2 trial of BOVen with ΔMRD400-directed treatment duration is ongoing.
Clinical • P2 data
|
clonoSEQ
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
16d
Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing (ASH 2024)
We selected 108 CLL patient samples with genetic annotation and exposed them ex-vivo to small-molecule inhibitors used clinically (ibrutinib/BTKi, duvelisib/PI3Ki, trametinib/MEKi, everolimus/mTORi, selinexor/XPO1i) or targeting key signaling pathways (compound 26/TLRi, MK2206/AKTi, nutlin-3a/MDM2i, IBET872/BETi) for 48h. In conclusion, the addition of targeted pathway perturbations to the GEP of primary CLL samples can greatly enhance the potential for molecular and functional classification of disease and subgroups. Our study provides a blueprint to use perturbed omics profiling and interaction testing to link disease drivers to pathway activation and function.
IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • TNFA (Tumor Necrosis Factor-Alpha)
|
TS 12
|
BluePrint
|
Mekinist (trametinib) • Imbruvica (ibrutinib) • everolimus • Xpovio (selinexor) • MK-2206 • Copiktra (duvelisib)
16d
Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis (ASH 2024)
ViPOR-P is safe without notable additional toxicity, especially neutropenia and neuropathy, compared to ViPOR, and DL3 was identified as the RP2D. Most AEs were hematologic and manageable with G-CSF with rare febrile neutropenia observed. Fixed-duration ViPOR-P x 6C without maintenance resulted in durable CRs, especially in pts with non-GCB DLBCL by IHC and ABC DLBCL by RNA-seq, including refractory and post-CAR-T pts.
Clinical • P1/2 data • Combination therapy • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule)
|
clonoSEQ
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)
16d
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181 (ASH 2024)
Induction with 3 cycles of bendamustine and rituximab followed by 3 cycles of cytarabine and rituximab (BR/CR) is associated with high complete metabolic response (CMR) and uMRD rates (Armand et al., BJH 2016; Merryman et al., Blood Adv 2020). Bruton’s tyrosine kinase inhibitors (BTKi) including ibrutinib and acalabrutinib (A) in combination with CIT are highly effective in MCL (Wang et al., EHA 2024, LBA 3439)... High PET/CT CMR uMRD rates were seen in all 3 arms. BR/CR can be considered as a standard induction in pts ≤ 70. Addition of acalabrutinib to the standard arm added toxicity without improvement in efficacy, suggesting acalabrutinib should be avoided during Ara-C cycles.
Clinical • P2 data • IO biomarker
|
clonoSEQ
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine
16d
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease (ASH 2024)
Fixed-duration ViPOR x 6C without maintenance achieved CR in 100% and uMRD in 97% of MCL pts, with ongoing CR in 95% and 73% of TN and R/R pts, respectively, and only 1 R/R pt receiving consolidative allo-HSCT. This includes blastoid, TP53 mutated, and post-BTKi high-risk subsets. ViPOR with a 12d VEN ramp-up on C2 is safe in MCL pts of all ages without significant TLS or febrile neutropenia.
Clinical • P1/2 data • Minimal residual disease
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1)
|
TP53 mutation • TP53 expression
|
clonoSEQ
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
16d
Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) (ASH 2024)
Introduction: Combined treatment with covalent BTK-inhibitor (cBTKi), such as ibrutinib, acalabrutinib, or zanubrutinib with BCL2-inhibitor, venetoclax, +/- CD20 monoclonal antibody obinutuzumab showed high rates of undetectable MRD (U-MRD4, 10-4 sensitivity) remission in patients (pts) with CLL (Jain, NEJM 2019; Munir NEJM 2023; Wierda, JCO 2021; Kater, NEJM Evidence 2022). We report results of combined pirtobrutinib, venetoclax, and obinutuzumab in pts with previously untreated CLL. We observed a very high rate of BM U-MRD6 at 6-months and 12-months of combined treatment. Adverse event profile was similar to what was noted in previous studies with these agents.
Clinical • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 mutation + Chr del(17p)
|
clonoSEQ
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib)
16d
Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (ASH 2024)
In preclinical studies, lenalidomide has been shown to induce cytotoxicity in ABC DLBCL cells by inhibiting NF-κB signaling and a synergistic effect is seen when B-cell receptor signaling is inhibited by the BTK inhibitor ibrutinib. The results of the BGB-3111-110 study demonstrated that the RP2D of zanubrutinib 160 mg twice daily plus lenalidomide 25 mg once daily had a manageable safety profile and promising efficacy in patients with R/R DLBCL. Similar efficacy was observed across DLBCL subtypes; ORR was numerically higher in the ABC subtype. Further molecular analysis is ongoing.
Clinical • P1 data • IO biomarker
|
HTG EdgeSeq DLBCL Cell of Origin Assay
|
Imbruvica (ibrutinib) • lenalidomide • Brukinsa (zanubrutinib)
16d
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia. (PubMed, Ann Hematol)
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. Moreover, ibrutinib remains an effective treatment after this combination. This study was registered on the clinicaltrial.gov web (NCT02962401, November 9, 2016).
P2 data • Journal
|
TP53 (Tumor protein P53) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
TP53 mutation • CXCR4 mutation
|
Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Zydelig (idelalisib)
17d
Trial completion date • Trial primary completion date • Adverse events • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
18d
Benefit VA: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
P2, N=100, Not yet recruiting, VA Office of Research and Development | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Jun 2029 --> Jun 2030
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
21d
Enrollment closed • Enrollment change
|
Imbruvica (ibrutinib) • Jakafi (ruxolitinib) • parsaclisib (INCB50465) • itacitinib (INCB039110)
24d
Trial completion date
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Imbruvica (ibrutinib) • Darzalex (daratumumab)
24d
ERADIC: Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia (clinicaltrials.gov)
P2, N=120, Active, not recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2026 --> Jan 2025
Trial completion date
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
|
TP53 mutation
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • cyclophosphamide
26d
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies. (PubMed, Cancers (Basel))
The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling...To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation...In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.
Review • Journal
|
PLCG2 (Phospholipase C Gamma 2)
|
BTK C481S • BTK C481
|
Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib)
27d
Bilateral Intraocular Involvement of Recurrent Mantle Cell Lymphoma with Remission of Pseudo-Uveitis and Secondary Glaucoma After Switching Treatment to Ibrutinib: A Case Report. (PubMed, Ocul Immunol Inflamm)
A 75-year-old man presented with uveitis masquerade syndrome while undergoing treatment for MCL with rituximab-bendamustine. During the study course, CD5 and CD20 positive cells were identified in the anterior chamber of the eyes via flow cytometry, which was consistent with the pathological findings of biopsies. Ibrutinib may improve recurrent MCL intraocular lesions.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
|
CD20 positive
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
30d
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial primary completion date: Mar 2025 --> Sep 2024
Trial primary completion date • Combination therapy
|
Imbruvica (ibrutinib) • lenalidomide
1m
FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia. (PubMed, J Clin Invest)
Knock-out or inhibition of FoxO1 or Rictor led to a dramatic decrease in Akt phosphorylation and growth disadvantage for malignant B cells in the presence of ibrutinib (or PI3K inhibitor idelalisib) in vitro and in vivo. FoxO1/Rictor/pAktS473 axis represents an early non-genetic adaptation to BCR inhibitor therapy not requiring PI3Kδ or BTK kinase activity. We further demonstrate that FoxO1 can be targeted therapeutically, and its inhibition induces CLL cells' apoptosis alone or in combination with BTK inhibitors (ibrutinib, acalabrutinib, pirtobrutinib) and blocks their proliferation triggered by T-cell factors (CD40L, IL-4, and IL-21).
Journal
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CD40LG (CD40 ligand) • IL21 (Interleukin 21) • IL4 (Interleukin 4)
|
Imbruvica (ibrutinib) • Calquence (acalabrutinib) • Zydelig (idelalisib) • Jaypirca (pirtobrutinib)
1m
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) (clinicaltrials.gov)
P2, N=200, Recruiting, Incyte Corporation | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2027
Trial completion date • Trial primary completion date
|
Imbruvica (ibrutinib) • Jakafi (ruxolitinib) • parsaclisib (INCB50465) • itacitinib (INCB039110)
1m
Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma. (PubMed, Cancer Sci)
Although the efficacy of carfilzomib was difficult to confirm due to its toxicity in our models, ibrutinib showed comparable efficacy to a standard combination of chemotherapy drugs. Together, our data provide a new culture method for IVLBCL PDX cells and a rationale for translating ibrutinib to clinical use in IVLBCL patients.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BTK (Bruton Tyrosine Kinase) • CD79B (CD79b Molecule)
|
CD79B mutation • CD79B mutation
|
Imbruvica (ibrutinib) • carfilzomib
1m
New P2 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab)
1m
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. (PubMed, EJHaem)
Hairy cell leukemia is an uncommon B-cell malignancy with excellent response to purine analogs and to targeted therapies such as ibrutinib and vemurafenib. Only one patient in our cohort passed away due to infection. Estimated 10-year overall survival was 99% suggesting that infections may not cause as much mortality as was seen prior to current therapies.
Journal
|
CD4 (CD4 Molecule)
|
Zelboraf (vemurafenib) • Imbruvica (ibrutinib)
1m
VEGA: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=36, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • bortezomib
1m
Comparing the Efficacy and Safety of First-Line Treatments for Chronic Lymphocytic Leukemia: A Network Meta-Analysis. (PubMed, J Natl Cancer Inst)
Tailored chemo-free regimens can be selected based on age, comorbidities, IGHV status, and cytogenetic abnormalities to optimize treatment outcomes while considering different response spectra.
Retrospective data • Journal • IO biomarker
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
|
TP53 mutation
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
1m
Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis. (PubMed, Ther Adv Med Oncol)
However, bendamustine + rituximab had a more favorable safety profile for grade ⩾3 AEs when compared with ibrutinib (risk ratio 0.62 (95% credible interval 0.40-0.86)), acalabrutinib (0.69 (0.45-0.94)), zanubrutinib (0.64 (0.42-0.91)), and venetoclax + rituximab (0.87 (0.79-0.96)). Our findings showed that venetoclax + rituximab, acalabrutinib, and zanubrutinib have acceptable safety profiles, which indicates that they may be the preferred therapeutic options in the setting of relapsed/refractory CLL. PROSPERO CRD42022304330.
Clinical • Retrospective data • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • bendamustine
1m
Trial completion date
|
Imbruvica (ibrutinib)
1m
IBDCL-GELTAMO-2015: Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT (clinicaltrials.gov)
P2, N=64, Completed, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Unknown status --> Completed
Trial completion
|
Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • oxaliplatin • dexamethasone
1m
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study. (PubMed, Hemasphere)
This large real-world study shows that ibrutinib is an effective treatment for R/R CLL. Baseline patient characteristics and double-hit TP53 aberrations were associated with inferior prognosis, and discontinuation due to CLL progression portended a poor outcome.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Imbruvica (ibrutinib)
1m
CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
P1/2, N=225, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 positive • BCL6 rearrangement • BCL2 rearrangement
|
Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
2ms
MERIT: Ibrutinib in Treating Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia After Front-Line Therapy (clinicaltrials.gov)
P2, N=35, Active, not recruiting, Mayo Clinic | Trial primary completion date: Dec 2024 --> Dec 2023
Trial primary completion date
|
Imbruvica (ibrutinib)
2ms
Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia. (PubMed, Leuk Lymphoma)
Importantly, the combination of OPN-51107 and venetoclax exhibited synergistic cytotoxicity in ibrutinib-resistant CLL cells and patient-derived CLL samples regardless of R/R or deletion status. This study establishes the preclinical efficacy of using OPN-51107 and venetoclax in combination in therapy-resistant and/or high-risk CLL, lending support for its further development as a combination therapy.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BRD4 (Bromodomain Containing 4)
|
TP53 deletion
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)
2ms
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=102, Completed, Oncternal Therapeutics, Inc | Active, not recruiting --> Completed
Trial completion
|
BCL2 (B-cell CLL/lymphoma 2)
|
Imbruvica (ibrutinib) • zilovertamab (UC-961)
2ms
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia (clinicaltrials.gov)
P2, N=18, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
Enrollment closed
|
Imbruvica (ibrutinib)
2ms
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. (PubMed, Blood)
Incidence of atrial fibrillation/flutter was lower with zanubrutinib vs ibrutinib (7.1% vs 17.0%); no cardiac deaths were reported with zanubrutinib vs six cardiac deaths with ibrutinib. This analysis, at 42.5 months median follow-up, demonstrates that zanubrutinib remains more efficacious than ibrutinib with an improved overall safety/tolerability profile.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 mutation + Chr del(17p)
|
Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
2ms
Characterisation of molecular mechanisms for PLCγ2 disease-linked variants. (PubMed, Adv Biol Regul)
Furthermore, many mutations discovered in PLCγ2 have been linked to the development of complex immune disorders as well as resistance to ibrutinib treatment in chronic lymphocytic leukaemia...These data, combined with the structural insights, suggest that the PLCγ2 P522R variant has subtle, localised structural changes that do not directly affect the PLC activity by compromising autoinhibition, as determined for PLCγ2 M1141K. It is also likely that in contrast to the PLCγ2 M1141K, the functional impact of the P522R substitution completely depends on further interactions with upstream kinases and other regulatory proteins in a relevant cellular context, where changes in the PLCγ2 P522R variant could facilitate processes such as phosphorylation and protein-protein interactions.
Journal
|
PLCG2 (Phospholipase C Gamma 2)
|
Imbruvica (ibrutinib)